SEC filing · 8-K

Biomarin Pharmaceutical Inc: Quarterly results

BioMarin expects third-quarter and full-year 2026 earnings to be reduced by charges related to its acquisition of Alesta Therapeutics.

Filed October 6, 2026

Negative for the company

What happened

BioMarin completed the acquisition of Alesta Therapeutics on August 31, 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Biomarin Pharmaceutical Inc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.